Yaoyuan Pharmaceutical

Yaoyuan Pharmaceutical is a clinical-stage biotechnology company based in Shanghai, China, dedicated to the discovery and development of novel small molecule therapeutics. The company leverages its proprietary Proteolysis Targeting Chimera (PROTAC) platform to develop protein degraders for targets that are difficult to address with traditional inhibitors. Its lead program, YY201, is an orally available androgen receptor degrader currently in clinical development for metastatic castration-resistant prostate cancer. Yaoyuan's pipeline also includes several preclinical programs targeting estrogen receptors and other key drivers in oncology. The firm is led by a team of experienced drug discovery scientists with a focus on addressing significant unmet medical needs in cancer treatment.